Live Breaking News & Updates on Current Study Design
Stay updated with breaking news from Current study design. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. The full text announcement is contained below and can be accessed on Achilles website at: https://achillestx.com/news .
Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertain ....
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials Phase I/IIa CHIRON and THETIS Trials London, UK 5 February 2021 - Achilles Therapeutics ( Achilles or the Company ), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. In this review of the first six patients dosed with the Company s Clonal Neoantigen Targeting T cell therapy (cNeTs), the overall tolerability profile was generally similar to that of standard tumor-infiltrating lymphocyte (TIL) products that have not been enriched for cNeT reactivities, with the lymphodepletion re ....